MED25

Across TCGA pan-cancer cohorts, MED25 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MED25 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MED25 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MED25 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

UCEC, LUAD, and PDAC are the cancer types where MED25 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	1.000	0.376	.013	36	view →
LUAD	DFS	Tertile	II,III,IV	0.762	0.183	.001	25	view →
PDAC	OS	Median	IV	0.973	0.540	.017	10	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	8	view →
LSCC	OS	Tertile	All	0.881	0.691	.024	6	view →
CCRCC	DFS	Quartile	III,IV	0.495	0.832	.024	4	view →
GBM	OS	Median	All	0.459	0.290	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MED25–UCEC (DFS)

Open the UCEC breakdown →